Lisa A Hasvold

This inventor holds 33 USPTO granted patents and 33 published patent applications, plus 6 CIPO patents and 16 EPO patents. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Genentech, Inc.. Active years: 1997-2024.

USPTO Granted Patents = 33 (Patent Applications = 33)

% Patents Active = 90.9

CIPO Patents = 6 (Patent Applications = 17)

EPO Patents = 16 (Patent Applications = 29)

Average Co-Inventor Count = 9.7

ph-index = 10

Forward Citations = 446(Granted Patents)

Company Filing History:

Abbott Laboratories Corporation

Walter and Eliza Hall Institute of Medical Research

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

Areas of Expertise:

Apoptosis Inducing Agents

Bromodomain Inhibitors

Isoindolone Derivatives

Pyrrole-3-Carboxamide Inhibitors

Mcl-1 Inhibitors

Dihydro-Pyrrolopyridinone Inhibitors

Bcl-2 Selective Agents

Heterocyclic Compounds

PIM Kinase Inhibitors

Farnesyltransferase Inhibitors

Cancer Chemotherapeutics

Chiral Amino-Pyrrolidine

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11897864 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases (2024-02-13),

2. 10633379 - Bromodomain inhibitors (2020-04-28),

3. 10131657 - Bromodomain inhibitors (2018-11-20),

4. 10035800 - Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors (2018-07-31),

5. 9957263 - Bromodomain inhibitors (2018-05-01),

6. 9776990 - Isoindolone derivatives (2017-10-03),

7. 9493411 - Pyrrole-3-carboxamide bromodomain inhibitors (2016-11-15),

8. 9359296 - 7-substituted indole Mcl-1 inhibitors (2016-06-07),

9. 9321764 - Dihydro-pyrrolopyridinone inhibitors (2016-04-26),

10. 9315488 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2016-04-19),

11. 9303025 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-04-05),

12. 9296741 - Bromodomain inhibitors (2016-03-29),

13. 9174982 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2015-11-03),

14. 9125913 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-09-08),

15. 9073855 - BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-07-07),

Title: **Lisa A Hasvold: A Trailblazer in Cancer Research and Therapeutics**

Introduction

Lisa A Hasvold is an accomplished inventor based in Grayslake, Illinois, known for her significant contributions to the field of cancer research and therapeutics. With an impressive portfolio of 33 patents, she has made substantial strides in discovering innovative treatments for various diseases, particularly those related to apoptosis and inflammatory conditions.

Latest Patents

Some of Lisa's latest patents reflect her dedication to advancing medical science. One notable patent is focused on "Apoptosis Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases," which discloses compounds that inhibit anti-apoptotic Bcl-2 proteins. These compounds offer new methods for treating diseases characterized by the expression of these proteins. Another significant invention by Lisa involves "Bromodomain Inhibitors," which provides a range of compounds useful in treating diseases such as inflammatory diseases, cancer, and AIDS, alongside their pharmaceutical formulations.

Career Highlights

Throughout her career, Lisa has significantly impacted the pharmaceutical industry by working with renowned companies such as AbbVie Inc. and Abbott Laboratories Corporation. Her experience in these organizations has equipped her with the skills and insights needed to drive innovation and success in her field.

Collaborations

Lisa has collaborated with talented professionals throughout her career, including her coworkers Le Wang and Steven Elmore. These partnerships have not only enhanced her research capabilities but also fostered a collaborative environment that encourages groundbreaking discoveries.

Conclusion

Lisa A Hasvold stands out as a key figure in the realm of therapeutic invention, particularly in cancer treatment and related fields. Her extensive patent portfolio and collaborative spirit reflect her commitment to improving health outcomes through innovative research. As she continues her work, Lisa remains a significant contributor to the advancements in modern medicine.